Should I Buy Moderna Stock in 2025? Complete Ireland Analysis

What is Moderna?

How much is the Moderna stock?

The price of Moderna stock is rising this week. As of now, Moderna (MRNA) trades at $26.93, with a 24-hour gain of $0.88 (+3.38%) and a weekly increase of 4.38%. The company holds a market capitalisation of $10.42 billion, with an average daily volume over the last three months of 10.68 million shares. The P/E ratio is not available due to recent net losses, no dividend yield is offered, and the stock beta stands at a notably high 2.00. This high volatility may interest investors in Ireland seeking dynamic exposure in the biotech sector.

Our full analysis of the Moderna stock

Having rigorously examined Moderna’s latest financial results and scrutinised the stock’s performance over the past three years, we have applied our proprietary methodology—blending high-frequency financial indicators, technical signals, market breadth data, and peer benchmarking—to form an integrated view of the investment case. Despite significant volatility and recent underperformance, our synthesis points to a company at the heart of biotech’s innovation cycle, with multiple value creation levers potentially aligning into 2025. So, why might Moderna stock once again become a strategic entry point into the next chapter of life sciences?

Recent Performance and Market Context

Over the past twelve months, Moderna’s share price has experienced a marked correction, currently trading at $26.93 as of 30 May 2025—down 81.8% year on year and 37.5% in the past six months. This decline is in part a technical reaction to pandemic-era overvaluation and the normalisation of COVID-related sales. However, more recent price action is showing distinct signs of stabilisation: a 4.4% rebound over the past week and an intraday jump of 3.4% suggest renewed tactical interest.

Several positive events underpin this turnaround. Firstly, the company successfully launched its RSV vaccine (mRESVIA®) in Q1 2025 and submitted its new-generation COVID-19 vaccine (mRNA-1283) for FDA approval, with crucial PDUFA dates imminent. Such regulatory milestones are well-known catalysts for sharp upward re-ratings in the biotech sector.

The broader sector context is also improving. After a challenging macroeconomic environment, risk appetite towards biotech is returning, sparked by falling inflation, stable discount rates, and renewed strategic M&A activity. For investors in the Irish and broader European markets, the US biotechnology sector—especially companies at the forefront of mRNA innovation—is increasingly attractive as a diversification play and a hedge against eurozone cyclicality.

Technical Analysis

Recent technicals highlight an emerging base-building phase for Moderna shares:

• Relative Strength Index (RSI): The 14-day RSI sits comfortably at 51.45, indicating neither overbought nor oversold conditions but rather a neutral momentum with upside potential.
• MACD: The MACD at -0.26 points to a mild, not deep, bearish undertone, with the recent flattening indicating a possible bottoming out.
• Moving Averages: The stock’s current price of $26.93 is virtually aligned with its 20-day moving average ($26.24), showing price stabilisation and the start of a potential trend reversal.
• Key Levels: The robust support zone at $23.15, near the 52-week low, has repeatedly held—reinforcing this price floor. Short-term resistance is clustered in the $30-35 zone; the consensus analyst price target stands at $47.70 (+77% upside vs. current).

In terms of structure, this technical configuration often signals a transition from capitulation to accumulation, an important stage for investors seeking asymmetric, risk-adjusted upside.

Fundamental Analysis

While Moderna is currently reporting net losses—Q1 2025 recorded revenues of $108 million (vs $167 million YoY), with a net loss of $(971) million—the fundamental picture offers substantial grounds for optimism:

• Revenue Growth Pipeline: Management guides $1.5-2.5 billion in revenue for 2025, reflecting a strong second-half weighting due to vaccine seasonality and the imminent commercial rollout of new products.
• Attractive Valuation: The share price now reflects a price-to-sales (P/S) ratio of just 3.3 and price-to-book (P/B) of 1.03—levels rarely seen in high-potential biotech, suggesting room for meaningful re-rating as profitability rebounds.
• Structural Strengths: Moderna is the leading mRNA platform company, with a uniquely diversified late-stage pipeline spanning vaccines for respiratory viruses, oncology, and rare diseases. Its R&D engine, strong IP portfolio, and proven commercialisation capabilities set it apart from competitors.
• Balance Sheet Resilience: With $8.4 billion in cash and investments (as of March 2025), Moderna has the flexibility to fund its ambitious clinical programme and weather transient market or regulatory headwinds.
• Operational Efficiency: Strategic cost-cutting has already delivered a 27% reduction year-over-year and is expected to yield a $1.4–1.7 billion decrease in annual operating expenses by 2027, aligning the company for improved margins as revenue stabilises.

Given these factors, the fundamentals not only justify renewed investor interest, but also point to a company entering the next phase of platform monetisation.

Volume and Liquidity

Moderna’s robust average daily traded volume—over 10.68 million shares—reflects continued institutional engagement and provides excellent liquidity for retail and professional investors alike. The free float, at over 342 million shares, ensures a dynamic market and facilitates smoother price discovery, limiting the risk of illiquidity discounts that often affect smaller biotech names.

Sustained volume, even during the recent correction, evidences a market that remains fundamentally engaged, awaiting defining positive news flow to catalyse the next major price move.

Catalysts and Positive Outlook

Multiple near- and medium-term catalysts are set to reshape the risk/reward profile:

• Regulatory Approvals: Key FDA decisions are due imminently for the next-generation COVID-19 vaccine (mRNA-1283, 31 May 2025) and the RSV vaccine for high-risk adults (12 June 2025). Beyond that, the combination flu/COVID-19 vaccine targets a late 2026 launch, with regulatory submissions underway.
• Data Readouts: Phase 3 readouts for the seasonal flu vaccine and norovirus programme are expected over the coming months, each with the potential to open new multi-billion-dollar verticals.
• Oncology Innovation: Moderna’s mRNA-4157 personalised cancer therapy is advancing through multiple pivotal trials, positioning the company to be a first-mover in a potentially transformative therapeutic paradigm.
• Rare Diseases: Active programmes addressing propionic acidemia and methylmalonic acidemia not only diversify risk but drive high unmet-need value.
• Strategic Partnerships and ESG: Moderna’s ongoing collaborations and a growing focus on sustainable business practices align it favourably with large institutional mandates and ESG-focused investment flows.
• Upward Sector Dynamics: The renewed regulatory support for mRNA vaccines, potential streamlined approval pathways, and increasing global vaccine demand act as powerful sector-wide tailwinds.

Cumulatively, these ongoing and upcoming milestones have the capacity to reignite both growth expectations and sentiment towards the stock, paving the way for a material re-rating.

Investment Strategies

• Short-Term Positioning: Entry ahead of key FDA decisions and summer Phase 3 vaccine data offers significant upside optionality, with defined technical support at $23. Should approvals be granted and data be positive, a momentum-driven rally is likely.
• Medium-Term Perspective: Targeting positions on periods of technical consolidation (e.g., near the 20-day MA or just above the $23.15 support) allows investors to ride new commercial launches and data events into late 2025 and early 2026.
• Long-Term Conviction: For those seeking growth beyond cyclical vaccine demand, Moderna’s pipeline diversification and platform technology underpin a multiyear runway for value creation, particularly as oncology and rare disease assets reach market. The current depressed valuation offers an attractive risk-adjusted anchor point for patient capital.

Is It the Right Time to Buy Moderna?

Moderna’s story is one of transformation: from pandemic champion through share price correction and now, potentially, to a new phase as a diversified, cash-rich, innovative leader in mRNA medicines. The convergence of multiple high-impact catalysts, robust financial positioning, exceptional technical support, and an attractive long-term valuation suggests that the stock now seems to represent an excellent opportunity for investors keen to re-enter the biotech space at favourable terms.

While no investment is without risk, the balance of evidence points to a company poised for dynamic recovery and growth, with imminent events likely to unlock new valuation territory. In this context, Moderna’s current levels may well justify renewed attention for discerning investors seeking exposure to the next wave of biotech breakthroughs and innovative healthcare solutions.

For those positioning for the rebound in biotech innovation, Moderna’s share price now appears to combine timing, valuation, and fundamental momentum in a way that is rarely seen in the sector.

How to buy Moderna stock in Ireland?

Buying Moderna stock online is straightforward and secure for Irish investors, provided you use a regulated broker. You have two main options to access Moderna (NASDAQ: MRNA): you can purchase real shares (“spot” buying) or trade Contracts for Difference (CFDs) that track the share price. Both methods are widely available with reputable online brokers catering to Ireland, offering transparent fees and flexible trading tools. Exploring the differences between these approaches, as well as comparing the fees and services of various brokers, is key—see further down for a detailed broker comparison tool.

Cash buying

Spot or cash buying means purchasing real shares of Moderna—these are held in your name, entitling you to direct ownership and all associated rights. With most Irish-friendly brokers, you are typically charged a fixed commission per order, often around $5 (approximately €5) per US share trade.

Informations importantes

For example: If the Moderna share price is $26.93, you could buy about 37 shares with a $1,000 investment (allowing $5 for commission).

✔️ Gain scenario: If the Moderna share price climbs 10% (to $29.62), your shares are now worth around $1,100 in total.
Result: That’s a $100 gross gain—delivering a +10% return on your investment, before taxes and other potential charges.

Trading via CFD

CFD trading allows you to speculate on Moderna’s share price without owning the underlying shares. Instead, you enter into a contract with your broker to capture the price movement. CFD trading generally comes with two types of fees: the spread (the small difference between buy and sell price) and, if you keep positions open overnight, a financing charge.

Informations importantes

Example: Let’s say you start with a $1,000 margin using 5× leverage—your market exposure equals $5,000.

✔️ Gain scenario: If Moderna shares rise by 8%, your position would return 8% × 5 = 40%.
Result: That’s a $400 gain on your $1,000 deposit (excluding spread and overnight costs). Remember, leveraged trading magnifies both potential gains and losses.

Final advice

Before investing in Moderna or any US-listed stock, be sure to compare broker fees, available account types, and support for Irish residents. Some brokers are better for long-term cash investment, others for active CFD trading. Your ideal method ultimately depends on your objectives and risk tolerance. For a detailed, up-to-date comparison of leading brokers in Ireland, check out the comparator further down the page.

Our 7 tips for buying Moderna stock

The latest news about Moderna

Moderna’s stock has risen 4.38% over the past week, outperforming many of its biotech peers. This uptick is particularly notable given a challenging environment for the broader sector and has occurred just ahead of several key regulatory catalysts for the company. The latest trading session closed at $26.93, placing the share price very close to its 20-day moving average, which signals technical stability and growing investor interest as critical FDA decision dates approach.

The FDA is expected to decide on Moderna’s next-generation COVID-19 vaccine (mRNA-1283) by 31 May 2025, supporting near-term growth prospects. This upcoming potential regulatory approval is highly relevant for institutional and retail investors in Ireland, given the continued rollout of COVID-19 vaccines across the EU, including the HSE’s programs. The decision could strengthen Moderna’s supply contracts and market position in Ireland and Europe, significantly improving revenue outlooks and bolstering sentiment among Irish market participants.

Moderna has substantial cash reserves of $8.4 billion (March 2025), ensuring business flexibility and resilience. This strong liquidity improves the company's risk profile and provides ample funding capacity for ongoing R&D and commercial expansion, an important consideration for Irish investors seeking stability amid recent sector volatility. With a robust balance sheet, Moderna can continue strategic European partnerships and potentially expand clinical trials or product distribution in EU markets, including Ireland.

The analyst consensus indicates a potential 77% upside, with a target price average of $47.70 and “Hold” recommendation. Despite recent losses and lower revenues in Q1 2025, the consensus among 19 respected analysts reflects optimism driven by the rich late-stage pipeline and imminent product approvals. This positive outlook is relevant for portfolio managers and private investors in Ireland looking for recovery opportunities in the US-listed biotech space.

Moderna’s cost reduction measures have already achieved a 27% cut in operational expenses year-on-year, driving efficiency gains. The ongoing drive to reduce costs—targeting $1.4 to $1.7 billion savings by 2027—positions the company to weather market fluctuations and maximize long-term margins. For Irish stakeholders evaluating biotechs’ sustainability, such discipline enhances Moderna’s competitive stance as it adapts to post-pandemic market realities and pursues further commercial opportunities across Europe.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.